Insight Molecular Diagnostics/$IMDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Insight Molecular Diagnostics
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
Ticker
$IMDX
Sector
Primary listing
Employees
57
Headquarters
Website
IMDX Metrics
BasicAdvanced
$207m
-
-$1.46
-
-
Price and volume
Market cap
$207m
52-week high
$8.51
52-week low
$2.33
Average daily volume
454k
Financial strength
Current ratio
2.542
Quick ratio
2.362
Long term debt to equity
-12.225
Total debt to equity
-28.706
Interest coverage (TTM)
-338.89%
Profitability
EBITDA (TTM)
-32.569
Gross margin (TTM)
51.05%
Net profit margin (TTM)
-2,454.64%
Operating margin (TTM)
-1,790.97%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-43.29%
Return on equity (TTM)
20,228.75%
Valuation
Price to revenue (TTM)
107.657
Price to book
-19.39
Price to tangible book (TTM)
-19.39
Price to free cash flow (TTM)
-7.637
Free cash flow yield (TTM)
-13.09%
Free cash flow per share (TTM)
-0.841
Growth
Revenue change (TTM)
-49.28%
Earnings per share change (TTM)
-56.22%
3-year revenue growth (CAGR)
30.60%
3-year earnings per share growth (CAGR)
-47.99%
10-year earnings per share growth (CAGR)
-16.63%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Insight Molecular Diagnostics stock?
Insight Molecular Diagnostics (IMDX) has a market cap of $207M as of May 16, 2026.
What is the P/E ratio for Insight Molecular Diagnostics stock?
The price to earnings (P/E) ratio for Insight Molecular Diagnostics (IMDX) stock is 0 as of May 16, 2026.
Does Insight Molecular Diagnostics stock pay dividends?
No, Insight Molecular Diagnostics (IMDX) stock does not pay dividends to its shareholders as of May 16, 2026.
When is the next Insight Molecular Diagnostics dividend payment date?
Insight Molecular Diagnostics (IMDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Insight Molecular Diagnostics?
Insight Molecular Diagnostics (IMDX) does not currently have a Beta indicator.